Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

NCT02593929 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: ruxolitinib

Sponsor

University of Pittsburgh